© 2022 MJH Life Sciences and Cancer Network. All rights reserved.
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
November 05, 2021
Concluding their discussion on newly diagnosed multiple myeloma, expert panelists consider treatment options for patients with high-risk disease.
October 29, 2021
Shared insight on the evolving treatment landscape of transplant-ineligible newly diagnosed multiple myeloma.
May 03, 2021
Dr Sagar Lonial, MD, FACP, shares his thoughts on the future of targeted therapies for patients with multiple myeloma.
Sagar Lonial, MD, FACP, provides insight on the potential role of BCMA-targeted therapies for newly diagnosed patients with multiple myeloma.
A leading myeloma expert reviews important data that led to the approval of belantamab mafodotin for heavily pretreated patients with relapsed/refractory multiple myeloma.
Sagar Lonial, MD, FACP, reviews targeted therapy options, and how they differ from other therapeutic approaches for relapsed/refractory myeloma.
A multiple myeloma expert introduces and defines relapsed/refractory myeloma and discusses typical treatment strategies.